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Abstract
Background: Licensed human vaccines can induce various adverse events (AE) in vaccinated patients. Due to the
involvement of the whole immune system and complex immunological reactions after vaccination, it is difficult to
identify the relations among vaccines, adverse events, and human populations in different age groups. Many
known vaccine adverse events (VAEs) have been recorded in the package inserts of US-licensed commercial vaccine
products. To better represent and analyze VAEs, we developed the Ontology of Vaccine Adverse Events (OVAE) as
an extension of the Ontology of Adverse Events (OAE) and the Vaccine Ontology (VO).
Results: Like OAE and VO, OVAE is aligned with the Basic Formal Ontology (BFO). The commercial vaccines and
adverse events in OVAE are imported from VO and OAE, respectively. A new population term ‘human vaccinee
population’ is generated and used to define VAE occurrence. An OVAE design pattern is developed to link vaccine,
adverse event, vaccinee population, age range, and VAE occurrence. OVAE has been used to represent and classify
the adverse events recorded in package insert documents of commercial vaccines licensed by the USA Food and
Drug Administration (FDA). OVAE currently includes over 1,300 terms, including 87 distinct types of VAEs associated
with 63 human vaccines licensed in the USA. For each vaccine, occurrence rates for every VAE in different age
groups have been logically represented in OVAE. SPARQL scripts were developed to query and analyze the OVAE
knowledge base data. To demonstrate the usage of OVAE, the top 10 vaccines accompanying with the highest
numbers of VAEs and the top 10 VAEs most frequently observed among vaccines were identified and analyzed.
Asserted and inferred ontology hierarchies classify VAEs in different levels of AE groups. Different VAE occurrences
in different age groups were also analyzed.
Conclusions: The ontology-based data representation and integration using the FDA-approved information from
the vaccine package insert documents enables the identification of adverse events from vaccination in relation to
predefined parts of the population (age groups) and certain groups of vaccines. The resulting ontology-based VAE
knowledge base classifies vaccine-specific VAEs and supports better VAE understanding and future rational AE
prevention and treatment.
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Background
Many licensed vaccines exist to protect against a variety
of diseases and infections. They are extremely useful in
decreasing infection prevalence in human populations. Due
to the public health benefits of vaccines, their coverage has
been increasing in recent years. However, each vaccine
often induces different types of adverse events (AEs).
As vaccine usage increases, the risk of adverse events
proportionally increases [1]. There is a need to predict
probabilities of different adverse events arising in different
individuals, which can potentially lead to a decline in the
risk of developing an adverse event. Many known vaccine
adverse events (VAEs) at the population level have been
recorded in the package inserts of commercial vaccine
products. The VAE information in the package inserts
may be used for systematic VAE analysis and comparison,
providing a fundamental basis for further individual level
VAE evaluation and prediction.
Two existing ontologies are closely related to the VAE
studies. The Ontology of Adverse Events (OAE) is a
community-based biomedical ontology in the area of
adverse events [2,3]. OAE defines an ‘adverse event’ as a
pathological bodily process that occurs after a medical
intervention (e.g., vaccination, drug administration). The
OAE ‘adverse event’ is a subclass of the ontology term
‘pathological bodily process’ defined in the Ontology of
General Medicine Science (OGMS) (http://code.google.
com/p/ogms/). To be consistent with most practical uses
of the term, OAE does not assume a causal relation
between an ‘adverse event’ and a medical intervention.
OAE has defined over 2,000 types of adverse events
that are commonly found in different medical interventions.
The community-based Vaccine Ontology (VO) represents
various vaccines, vaccine components, and vaccinations
[4,5]. Both OAE and VO are OBO Foundry library ontol-
ogies and are developed by following the OBO Foundry
principles [6].
OAE has been shown to significantly increase the
power of analyzing often noisy case report data from the
Vaccine Adverse Event Reporting System (VAERS) [3].
In this study, the adverse events associated with killed
attenuated and live attenuated influenza vaccines were
separately extracted from VAERS, statistically analyzed,
and compared with each other. The AEs annotated and
stored in VAERS were assigned to the Medical Dictionary
for Regulatory Activities (MedDRA) codes [7]. Compared to
MedDRA, OAE was found to be better to classify the
groups of AEs associated with different types of influenza
vaccines, and biologically significant findings were generated
[3]. Due to the lack of randomized, well-controlled studies,
it is often difficult to justify the causality between an adverse
event reported and a vaccine administration using the
VAERS or other clinical case report data. However,
the results cited from the package insert documents
of FDA licensed vaccines were typically generated from
randomized, well-controlled clinical trials. Compared to
the noisy data from clinical VAE case reports, the adverse
events recorded in the official package inserts are known
adverse events specific for individual vaccines. To our
knowledge, there has been no published paper in the
ontological domain to analyze commonly known VAEs
recorded in the FDA package insert documents.
To better represent various VAEs and support vaccine
safety study, we developed the Ontology of Vaccine Adverse
Events (OVAE) as an extension of the biomedical ontologies
OAE and VO. In this paper, we introduce the basic frame-
work of the OVAE and how OVAE is used to represent and
analyze all adverse events reported in the product package
inserts of 63 FDA approved commercial vaccines currently
used in the USA market.
Results
OVAE system design and statistics
The goal of current OVAE development is to generate
an ontology-based VAE knowledge base that represents
known adverse events (AEs) associated with licensed
vaccines. Such a knowledge base incorporates the OAE
terms of AEs together with the vaccine information defined
in the VO. As the primary developer of the OAE and VO,
we argue that OAE is not appropriate or responsible for
representing various AEs specific for any particular medical
intervention including vaccination due to the following
reasons. First, OAE emphasizes the representation of
various AEs general for most medical interventions,
and related topics (e.g., methods for analysis of the
causal relation between AEs and medical interventions,
and factors affecting the causality analysis). Currently
OAE is already large and contains nearly 3,000 terms. It is
expected that many more AE terms will be added to OAE.
Therefore, it is ideal to make OAE focused and as
concise as possible. Secondly, AE researchers related
to specific medical intervention domains may have more
domain-specific demands and requests. For example, VAE
researchers would like to link AEs to different vaccines.
The drug researchers may prefer to associate AEs with
specific drugs. The vaccine (or drug) researchers may
not be interested in drug (or vaccine) specific AEs. As a
relatively independent domain, VAEs have been focuses of
many vaccine researchers and groups. Independent from
drug AEs, clinical VAEs are reported to vaccine-specific
VAERS system in the USA [8]. Meanwhile, the Vaccine
Ontology (VO) is not suitable for representing complex
VAE data. VO has been focused on classification of
various vaccines, including licensed vaccines, vaccines
in clinical trials, and vaccines only verified in laboratory
animal models. VO also represents various types of vaccine
components (e.g., vaccine antigens, adjuvants, and vectors),
vaccine attributes (e.g., vaccine organism viability and
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virulence), vaccination methods, and other concise and
closely related vaccine information. The inclusion of
complex and large VAE information to VO would
make VO imbalance and not specific enough. Due to
these reasons, we generated the VAE-specific OVAE,
which is an extension of OAE and VO. OVAE specifies
AEs associated with various vaccines, for example, influenza
vaccine Afluria-associated pain adverse event. The logical
definition of such a VAE requires both the pain AE term
from OAE and the Afluria vaccine term from VO. Such a
term cannot be captured without the OVAE. The OVAE
integration of OAE and VO is also required to link
such a term to related features about the AE and vaccine,
for example, the parent term of pain AE and the patient
age requirement for the vaccine administration. Since
both OAE and VO use the Basic Formal Ontology (BFO)
(http://www.ifomis.org/bfo) as the top level class, the
alignments between OVAE, OAE, and VO are easy and
straightforward.
As an extension of OAE and VO, OVAE targets for not
only importing related terms from these two ontologies but
also including many OVAE-specific terms. The primary
data source for generating vaccine-specific AE ontology
terms in current OVAE is the official vaccine package
inserts available in the USA FDA website [9]. Each official
vaccine package insert document provided by the USA
FDA includes a section called “Adverse Reactions”. The
results provided in the section were obtained from carefully
designed clinical trials with randomized controls and
worldwide post-marketing experience. Therefore, the VAE
information provides basic known VAEs that are likely to
occur after an administration of a specific vaccine in
a human vaccinee. Based on the officially documented
information, OVAE includes many OVAE-specific terms,
for example, ‘Afluria-associated pain AE’ to define a pain
AE specific for Afluria-vaccinated patients. As shown in
detail later in the paper, the generation of these new terms
allows the inclusion of more detailed information about
these VAEs, for example, the VAE occurrences in human
vaccinee populations in different age groups.
Table 1 lists the OVAE statistics as of July 1, 2013.
OVAE used the most recent BFO 2.0 Graz version
(http://purl.obolibrary.org/obo/bfo.owl) as the top level
ontology. Since BFO 2.0 is not yet finalized, some relation
terms (e.g., ‘part of ’ or BFO_0000050) are still used in
OVAE but do not necessarily comply with the most recent
BFO 2.0. During the process of importing many AEs or
vaccine-related terms from OAE and VO to OVAE,
many terms from other existing ontologies, including
OGMS, Ontology for Biomedical Investigation (OBI) [10],
Phenotypic Quality Ontology (PATO) [11], and Information
Artifact Ontology (IAO) (http://code.google.com/p/
information-artifact-ontology/), have also been imported
to OVAE (Table 1). To maintain the ontology asserted and
inferred hierarchies and support intact reasoning capabil-
ity, the OntoFox software was used for external term
importing [12]. In summary, OVAE contains 1,327
terms, including 626 OVAE-specific terms (with “OVAE_”
prefix). In addition, OVAE includes many ontology terms
from external ontologies, for example, all 128 terms from
the BFO version 2.0, 197 VO terms, 120 OAE terms, 16
OBI terms, 6 IAO terms, and 2 OGMS terms (Table 1).
By referencing the vaccine package insert data, OVAE
represents 87 distinct AEs associated with 63 licensed
human vaccines.
OVAE design pattern of representing VAE
The general design pattern of representing a VAE in
OVAE is shown in Figure 1. Specifically, a licensed
vaccine, manufactured by a company and having spe-
cific quality (e.g., using inactivated vaccine organism),
is targeted to immunize a human vaccinee against infection
of a microbial pathogen. A particular vaccination route
(e.g., intramuscular route) is specified. A specific VAE
(e.g., Afluria-associated injection-site pain adverse event)
occurs in a human vaccinee and after (preceded_by) a
vaccination. The human vaccinee, having a specific age
(defined via a datatype) at the time of vaccination, is part of
the population of human vaccinees using this vaccine. The
VAE occurrence is defined as a frequency of an adverse
event associated with the administration of a vaccine in a
vaccinee population. The new object property term ‘has
VAE occurrence’ is defined in OVAE to specify a VAE
occurrence (xsd:decimal datatype) in a human vaccinee
population that has been individually vaccinated with a
specific vaccine during a specific time period. To simplify
the representation of axioms linking vaccine adverse
Table 1 Summary of ontology terms in OVAE
Ontology
names
Classes Object properties Data properties Total
OVAE 626 1 1 628
BFO 40 88 0 128
CHEBI 7 0 0 7
OBI 8 8 0 16
PATO 7 0 0 7
IAO 6 0 0 6
NCBOTaxon 81 0 0 81
OAE 119 1 0 120
OGMS 2 0 0 2
RO 0 15 0 15
UBERON 105 15 0 220
VO 188 6 3 197
Total: 1189 124 4 1,327
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event and human vaccinee population, OVAE generates a
shortcut relation ‘occurs in population’ (Figure 1).
The vaccine attributes and vaccination details are
imported from VO. Their inclusion in the design pattern
is due to their possible contribution to the VAE determin-
ation. For example, a live attenuated vaccine and a killed
inactivated vaccine may in general induce different
types or levels of VAEs, which can be analyzed by
statistical analysis [3].
One novelty in the design pattern is the generation
and application of the population term ‘human vaccinee
population’ to define a VAE occurrence. In previous
versions of OAE and VO, only ‘vaccinee’ and ‘human
vaccinee’ (i.e., a human being administered with a vaccine)
exist. However, it is incorrect to say that a specific
human vaccinee has a VAE occurrence of some per-
centage (e.g., 10%). An occurrence is defined only for
a population. The generation of the term ‘human vac-
cinee population’ solves the ontology modeling issue.
Any particular human vaccinee is part of a human
vaccinee population.
There are two different approaches for representing the
relation between a human vaccinee (or human vaccinee
population) and an age (or age range). One approach is to
link a vaccinee to a quality named ‘age’, and then link
the ‘age’ to a datatype using the OBI relation term ‘quality
measured as’. Another approach for representing the
relation is to generate a shortcut relation ‘has age’
(or specifically ‘has age in year’). To make the representa-
tion simpler and reasoning efficient, we have taken
the second choice. The use of the relation ‘has age’
will need to specify the data value as well as the unit of
the data (e.g., year). The use of the shortcut relation ‘has
age in year’ is much simpler, requiring only the data value.
An example is provided below (Figure 2).
Generation of OVAE covering FDA package insert
AE information
Based on the design pattern described above, the OVAE
was generated to cover the AE information extracted
from the FDA package insert documents [9]. The FDA
website includes supporting materials for most human
vaccines licensed in the USA [9]. The detailed methods
of how to manually annotate the VAE information and
represent the knowledge in OVAE are described in the
Methods section.
An example of OVAE representation of VAE is shown
in Figure 2. Briefly, Afluria has been associated with nine
different types of AEs, including injection-site pain AE
that has been defined in OAE (Figure 2A and 2B). For
each AE, it is likely that different VAE occurrences
are reported based on the age groups. OVAE uses
two datatype property terms (‘has age in year’ and ‘has
VAE occurrence’) to link vaccinee population groups
and VAEs associated with particular VAE occurrences
(Figure 2B). The “OR” clause is used to include vaccinee
populations with different age ranges. The information
matches to the FDA package insert information (Figure 2C).
The FDA package insert citation was also used as a
definition source (annotation property).
SPARQL query of OVAE data
The SPARQL Protocol and RDF Query Language (SPARQL)
is a query language for querying and manipulating
data stored in a RDF tripe store. SPARQL is a standard rec-
ommended by the World Wide Web Consortium (W3C),
and is recognized as a key technology of the Semantic
Web. SPARQL 1.1 has been the official version since
March, 2013 [13]. SPARQL queries allow for triple patterns,
conjunctions, disjunctions, and optional patterns.
Figure 1 OVAE design pattern of a human vaccine adverse event.
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Figure 3 demonstrates an example of how to use
SPARQL to count the number of specific adverse events
for each vaccine. Figure 3A is a SPARQL script for
querying OVAE in a RDF triple store. In this SPARQL
query, the source of the OVAE ontology is specified
following the “FROM” keyword. In this script, the
variables “?pclass” and “?cclass” are two classes with
their labels (rdfs:label) “?plabel” and “?clabel”, respectively.
The child class “?cclass” is a subclass (rdfs:subClassOf) of
the parent class “?pclass”. A regular expression (regex)
filter function requires that the string “?plabel” include the
words “adverse events”, for example, “Recombivax HB
vaccine adverse event”. Another regex filter function
specifies the inclusion of the word “associated” in the
subclass label “?clable”, for example, “Recombivax
HB-associated fever AE”. These two regex functions
are designed based on the naming convention defined
in OVAE. Specifically, a bottom-level vaccine-specific
adverse event term label always uses the words “associated”
and “AE” (instead of “adverse event”), and its parent
vaccine-specific term label always contains the words
“adverse event” (instead of the abbreviation version “AE”).
To display the results, the SELECT function in the
script specifies “?pclass”, “?plabel”, and the total count
of “?cclass” in a decreasing order (“DESC”) based on
the count. The top eight query results are shown in
Figure 3B.
In this study, different SPARQL scripts were generated
to address different questions as exemplified below.
OVAE VAE data analysis results
After all VAEs found in FDA licensed vaccines are
represented in OVAE, the quality of the ontology was
manually annotated, and an ontology reasoner [14] was
used to ensure no logical errors occurring in the ontology
formation. To address scientific questions associated with
different vaccine AEs, the OVAE ontology was queried
using SPARQL. The Protege-OWL editor also provides
user-friendly function to directly visualize OVAE results.
Below we provide examples to illustrate how the analysis
of the OVAE knowledge base can be used to answer
different VAE questions.
First, those vaccines that are associated with the largest
number of VAEs were analyzed (Table 2). It is interesting
that many of these vaccines protect against meningitis, which
can be caused by different pathogens including Haemophilus
influenza type b (Comvax and PedvaxHIB), Neisseria
meningitides (Menactra), and Streptococcus pneumonia
(Prevnar 13). The list also includes three tetanus vaccines
and two Hepatitis B vaccines (Table 2). The relation between
these common diseases/pathogens and the high variety of
VAEs reported is unclear and deserves further investigations.
It is noted that the information does not dictate the severity
of AEs associated with each vaccine, but instead indicates
that those FDA-licensed vaccines display the most variation
in their reported AEs.
Secondly, we evaluated the top VAEs that have been
reported most frequently among all vaccines licensed in
the USA and represented by OVAE (Table 3). Most of
Figure 2 OVAE representing Afluria VAEs reported in FDA vaccine package insert. (A) The hierarchical structure of Afluria VAEs represented
in OVAE. (B) OVAE axiom representation of ‘Afluria-associated injection-site pain AE’ based on three age groups. (C) Afluria adverse reactions
recorded in the FDA package insert document. Other VAEs shown in the FDA package inserts are also represented in OVAE. The subfigures
(A) and (B) were screenshots of OVAE using the Protégé OWL editor. The text from (C) comes from the FDA package insert document of the
Afluria vaccine.
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the top 10 frequently observed VAEs are expected, such as
injection-site pain and redness, fever, and local swelling.
The headache and myalgia (i.e., muscle pain) are two
subtypes of pain. The pain AE, malaise (i.e. uneasiness and
discomfort) AE, and fatigue AE are all subtypes of behavior
and neurological AEs. The frequent occurrence of behavior
and neurological AE is likely associated with the common
intramuscular route used for vaccine administration.
Specific microbial antigen contents may also induce
frequently observed VAEs (e.g., fever). It is noted that
the information does not dictate which VAEs are the
most severe, but indicates which VAEs are commonly
observed in currently licensed vaccines in the USA.
To better understand the top VAEs associated with
licensed human vaccines, the hierarchical structure of
the top 10 VAEs (Table 3) was extracted using the
tool OntoFox and visualized using Protégé ontology
editor (Figure 4). The hierarchical visualization indicates
that most of the top ranked VAEs belong to the behavior
and neurological AE branch. It is also noted that after rea-
soning, two adverse events (e.g., injection-site pain AE)
were inferred to be subclasses of ‘injection-site adverse
event’ (Figure 4B). Since OAE does not allow multiple
inheritance, injection-site pain AE cannot be asserted
under both ‘pain AE’ and ‘injection-site adverse event’. In
OAE, injection-site pain AE is asserted under ‘pain AE’
which occurs in an injection site. A reasoner will be able
to infer it as a subclass of ‘injection-site adverse event’ as
well (Figure 4B). The ontology reasoning provides additional
power in VAE classification.
Furthermore, we compared the VAEs and VAE occur-
rences under different age groups. As shown in Figure 2,
the OVAE clearly represents the associations between
VAEs, the VAE occurrence rates, and different ages
(in years) of human vaccinee population. Our analysis
can further identify which age category has a higher
Figure 3 Example SPARQL for OVAE query. This example queries the numbers of specific adverse events associated with individual vaccines.
The SPARQL script is shown at the top. Below the script is the results obtained after execution of the SPARQL query. See the text in the
manuscript for detailed explanation.
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probability of experiencing any specific adverse events. For
example, we found that Salmonella typhi vaccine Typhim
Vi is associated with injection-site tenderness adverse
events with the highest rate of 97.5% at the age group of
18–40 years old. Based on the classification of “child”,
“adult”, and “child-adult” described in the Methods section
in the paper, there are 240, 160, and 177 vaccine-specific
AEs in the age categories “child”, “adult”, and “child-adult”,
respectively. It is also found that in general the VAE
occurrences shown in the children are typically higher
than those in adults. This suggests that individuals
under 18 years may be more likely to experience an
adverse reaction after vaccination.
The above examples illustrate the advantages of OVAE
in VAE data integration and analyses. The usage of
OVAE provides an efficient approach to answer different
VAE questions, which would be very difficult to address
without such an ontology.
Discussion
The development of OVAE is aimed to align and reuse
existing ontologies OAE and VO, and systematically repre-
sent and analyze vaccine-specific adverse events (VAEs).
As demonstrated in this report, such a strategy has many
advantages. First, as shown in Figure 2, the ontological
classification is easy for humans to interpret and analyze. A
human can browse the hierarchical tree to quickly under-
stand which VAEs are typically associated with a licensed
vaccine. Secondly, the ontology OWL representation is also
interpretable by computers and software programs. New
programs can be developed to parse and analyze the infor-
mation. Thirdly, the approach of aligning OVAE with exist-
ing ontologies allows efficient integration of data presented
in other ontologies (e.g., VO). Fourthly, the usage of OVAE
and other related ontologies makes it possible to analyze
VAEs with various tools such as VO-based literature
mining [15]. Eventually, an ontology-based linked VAE
data system can be generated.
Furthermore, it is possible to apply the OVAE framework
to analyze clinical VAE data such as those case reports
stored in VAERS [8]. For example, by comparing the
reported vaccine-specific VAE cases in VAERS with the
VAE occurrences reported in the package inserts and
OVAE, it is easy to differentiate known VAEs and possibly
new VAEs associated with the vaccine. Many differences
exist in terms of the data shown in the package inserts and
in VAERS database. While the data in the package inserts
were typically obtained from well controlled clinical trials,
clinical VAE case reports stored in VAERS came from
random reports from physicians, patients, patients’ parents,
or other sources. The VAERS database does not indicate
the total number of vaccinated human vaccinees in any
given period, making it impossible to calculate exact VAE
occurrences. However, an ontological approach in combin-
ation with a statistical analysis is still useful in VAERS data
analysis as previously demonstrated [3]. Currently the AE
data stored in VAERS are annotated using the Medical
Dictionary for Regulatory Activities (MedDRA), a coding
vocabulary nomenclature commonly used for clinical
adverse event recording and normalization [16]. However,
many disadvantages of MedDRA, including the lack of
term definitions and a well-defined hierarchical and logical
structure, prevent its effective usage in VAE term classifica-
tion. Our previous study showed that a mapping between
MedDRA and OAE terms followed by the application of
OAE hierarchy provided a feasible solution for valid classi-
fication of VAEs detected through statistical analyses of
VAERS data [3]. MedDRA does not have rich axiomatiza-
tion as shown in OAE and OVAE. The richer and verified
ontological axiomatization will facilitate VAE data analysis.
Table 2 Top 10 vaccines with the largest variety of VAEs
reported
Vaccine (disease or pathogen) VO_ID Total # VAE
Recombivax HB (Hepatitis B) VO_0010737 20
Comvax (Hib meningitis, Hepatitis B) VO_0000028 19
Menactra (Neisseria meningitidis) VO_0000071 18
Tetanus and Diphtheria Toxoids VO_0000111 18
Absorbed by MA Biological
(Tetanus, Diphtheria)
Prevnar 13 (Streptococcus pneumonia) VO_0000090 16
PedvaxHIB (H. influenzae type b) VO_0000083 15
RabAvert (Rabies) VO_0000094 14
JE-Vax (Japanese Encephalitis) VO_0000066 13
Tetanus Toxoid (boost only) (Tetanus) VO_0000984 13
Tetanus Toxoid Absorbed (Tetanus) VO_0000048 13
Note: The disease or pathogen name specified next to a vaccine name
indicates the disease or pathogen infection against which the vaccine is used.
The three bacteria listed (shown by italicized words) can all induce meningitis.
The vaccines are sorted based on the VAEs recorded in their package
insert documents.
Table 3 Top 10 most frequently reported VAEs
AE name OAE_ID Total # vaccines %
Injection-site pain AE OAE_0000369 43 68.3
Headache AE OAE_0000377 39 61.9
Fever AE OAE_0000361 34 54.0
Local swelling AE OAE_0001139 30 47.6
Injection-site redness AE OAE_0001546 25 40.7
Irritability AE OAE_0001105 23 36.5
Malaise AE OAE_0000390 21 33.3
Injection-site erythema AE OAE_0000644 20 31.7
Myalgia AE OAE_0000375 19 30.2
Fatigue AE OAE_0000034 18 28.6
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As an extension of both OAE and VO, OVAE represents
various VAEs associated with different licensed vaccines.
One future research direction will be to identify novel
ways to better analyze VAE clinical data using OVAE. Indeed,
one effective way is to develop an OVAE-based "Linked
Data" (LD; http://www.w3.org/standards/semanticweb/data)
system specifically for representing and sharing various VAE
clinical and research "instance" data obtained from VAERS
and other resources. Advanced reasoning methods can
then be developed to analyze the large but well-organized
data in the linked data system. Such an strategy is being
designed and implemented in our group.
While many AEs are common, different vaccines
are associated with different AEs with various molecular
mechanisms. The classification of different vaccine-specific
AEs allows us to examine the similarities and difficulties of
molecular interactions and pathways underlying different
types of VAEs. Various Omics and informatics tools can
also be applied. Therefore, the ontology representation
of vaccine-specific AEs is a first step towards refined
deep understanding of vaccine adverse events. The better
understanding of the vaccine-specific AE patterns and the
underlying molecular mechanisms will make it possible to
rationally design practical measures to prevent and treat
VAEs and thus support public health.
In addition to the VAEs associated with USA licensed
vaccines, the OVAE can be used to represent VAEs
associated with vaccines licensed in other countries. It is
also noted that the method of establishing vaccine-specific
OAE extension may likely be applied for developing
OAE extensions in other specified domains such as
drug-associated adverse events.
Conclusions
The Ontology of Vaccine Adverse Events (OVAE) onto-
logically represents and classifies various identified vac-
cine adverse events (VAEs) associated with human
vaccines licensed for use in the USA. Systematical ana-
lysis of the OVAE data improves the understanding of
vaccine-specific VAEs, making it possible to rationally
design VAE prevention and treatment measures and to
benefit public health.
Methods
OVAE ontology generation
Following VO and OAE, OVAE is also edited with the
Web Ontology Language (OWL2) format (http://www.
w3.org/TR/owl-guide/). FDA-licensed human vaccines
represented in VO were imported to OVAE using the
tool OntoFox [12]. Those adverse event terms reported
in the package inserts of FDA licensed human vaccines
were also imported to the OVAE using OntoFox. New
OVAE-specific terms were generated with IDs containing
the prefix of “OVAE_” followed by seven auto-incremental
digital numbers and edited using the Protégé 4.2 OWL
ontology editor (http://protege.stanford.edu/). The Java-
based ELK OWL 2 reasoner [14] was used for OVAE
ontology reasoning.
Figure 4 Classification of top 10 AEs associated with licensed human vaccines in the US. These OAE terms have been imported to OVAE
using OntoFox and visualized using Protégé OWL editor. (A) Asserted hierarchy in OAE; (B) Inferred hierarchy after reasoning.
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Data source of known VAEs
The official FDA website that provides supporting
documents of licensed vaccines was the primary data
source [9]. A PDF version of a package insert docu-
ment is available for almost every vaccine in the data
source. The PDF document includes a section called
“Adverse Reactions” that contains text descriptions of
known vaccine adverse events associated with the
vaccinated population.
Data collection and formatting to ontology
Based on the OVAE framework and the adverse event
description in the package inserts, a design pattern was first
generated to lay out the relations between different ontol-
ogy classes, properties, terms and data types (Figure 1). The
design pattern was used to form an MS Excel template for
collection of individual adverse events for different vaccines.
The MS Excel template includes the following categories:
vaccine name, vaccine VO ID, VAE location, VAE name in
package insert, VAE name in OAE, OAE ID, age category,
age years, VAE occurrence, and reference. Data for each
category was manually collected from individual vaccine
package inserts and then input into the Excel template. The
VAE location is listed as either injection-site or systemic.
The injection-site location is incorporated as part of the
OAE term, while the systemic AEs are set up as default.
Age categories included child (typically under 18 years old),
adult (above 18 years old), senior (above 65 years old), or
child-adult (all ages). Specific ages are concerted to years
and presented to comply with the OWL format. Each VAE
is referenced by the package insert citation. Following the
manual data collection and annotation, the program
Ontorat (http://ontorat.hegroup.org) was used to transform
the Excel file data to the OVAE ontology format [17].
VAE data analysis
To identify specific OAE or VO hierarchical structure among
a list of terms, OntoFox was first used to extract the input
OAE or VO terms and all associated terms required for
proper hierarchical assertion and inference. The output
OWL files were then visualized using a Protégé OWL editor.
SPARQL scripts were generated to query the OVAE
knowledge base from a RDF triple store that contains
the OVAE RDF triples. As an ontology in the OBO
Foundry ontology library (http://obofoundry.org/), OVAE
is automatically deposited in the Hegroup RDF triple store
[18]. The Hegroup triple store, the default OBO Foundry
library ontology RDF triple store, is used by Ontobee [18]
and can be queried through the Ontobee SPARQL query
interface (http://www.ontobee.org/sparql/). Our SPARQL
scripts were executed using the Ontobee SPARQL query
interface.
To identify specific OAE or VO hierarchical structure
among a list of terms, OntoFox was first used to extract
the input OAE or VO terms and all associated terms
required for proper hierarchical assertion and inference.
The output OWL files were then visualized using a
Protégé OWL editor.
OVAE project site, ontology dissemination, and licensing
The OVAE project website (http://www.violinet.org/ovae) is
located under VIOLIN, a comprehensive vaccine database
and analysis system [19]. OVAE has been deposited
to the BioPortal project of the National Center of Bio-
medical Ontology (NCBO) (http://bioportal.bioontology.
org/ontologies/3227). OVAE is also deposited in the
Ontobee linked data server (http://www.ontobee.org/
browser/index.php?o=OVAE) [18]. The OVAE source
code is available in a Google Code website: http://code.
google.com/p/ovae. The OVAE source is freely available
under the Apache License 2.0.
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